JOURNAL ARTICLE

Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ.

  • Published In: Bloomberg.com, 2025. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Tozzi, John; Smith, Gerry 3 of 3

Abstract

The article discusses Johnson & Johnson's (J&J) potential acquisition of Protagonist Therapeutics Inc., which is currently in talks, as reported by the Wall Street Journal. J&J has an existing partnership with Protagonist focused on developing therapies for immune conditions, including an experimental treatment for plaque psoriasis called icotrokinra, which has shown promising results in clinical trials. The acquisition could enhance J&J's portfolio, particularly as its immune treatment Stelara faces increased competition. Protagonist's stock experienced a significant increase following the news, reflecting investor optimism about the potential deal and the company's ongoing drug developments. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2025/10, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2025
  • Accession Number:188600596
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.